Further analysis using the UALCAN portal (based on TCGA-OV RNA-seq data; log2 (TPM+1) normalization) indicated that PLK1 expression did not significantly differ across clinical stages (FIGO I–IV), histological grades (G1–G3) or TP53 status of ovarian cancer (p > 0.05 for both comparisons, except for stage 2 vs. stage 4) (Figures 2B–D). This evidence concerns the gene PLK1 and ovarian carcinoma.